Skip to Content
Morningstar

Roche Holding AG ADR RHHBY

Morningstar Rating
Unlock
Stock PINX Rating as of
$30.41 +0.33 (1.10%)
View Full Chart
As of Delayed Price Post-Trading: $30.40 −0.01
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Roche's Pharma Pipeline and Diagnostics Innovation Support a Wide Moat

Karen Andersen

We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare giant is in a unique position to guide global health care into a safer, more personalized, and more cost-effective endeavor. Strong information sharing continues between Genentech and Roche researchers, boosting research and development productivity and personalized medicine offerings that take advantage of Roche's diagnostic expertise.

Read Full Report

Price vs Fair Value

View History
RHHBY is trading at a 45% discount.
Price
$30.05
Fair Value
$97.00
Uncertainty
Low
1-Star Price
$15.54
5-Star Price
$65.00
Economic Moat
Nvdhj
Capital Allocation
Xvhnmsgfb

Bulls Say, Bears Say

Bulls

Roche and its innovative U.S. arm Genentech have a solid history of generating blockbuster therapies in oncology, and Roche's pipeline is full of novel candidates, with a particularly large late-stage pipeline.

Bears

Roche's immuno-oncology drug Tecentriq was launched third to market behind Bristol's Opdivo and Merck's Keytruda, raising questions about Roche's innovation.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RHHBY is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$30.05
Day Range
$30.20–30.50
52-Week Range
$29.95–40.48
Bid/Ask
$30.40 / $30.45
Market Cap
$193.95 Bil
Volume/Avg
12.3 Mil / 2.3 Mil

Key Statistics

Price/Earnings (Normalized)
11.10
Price/Sales
2.89
Dividend Yield (Trailing)
4.63%
Dividend Yield (Forward)
4.63%
Total Yield
4.63%

Company Profile

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Core
Total Number of Employees
103,605
Website
https://www.roche.com

Competitors

Valuation

View More
Metric
RHHBY
ABBV
MRK
Price/Earnings (Normalized)
 11.1014.6383.48
Price/Book Value
 5.5227.718.44
Price/Sales
 2.895.315.31
Price/Cash Flow
 10.6414.3920.97
Price/Earnings
RHHBY
ABBV
MRK

Financial Strength

Metric
RHHBY
ABBV
MRK
Quick Ratio
 0.990.630.68
Current Ratio
 1.350.871.25
Interest Coverage
 14.933.572.33
Quick Ratio
RHHBY
ABBV
MRK

Profitability

Metric
RHHBY
ABBV
MRK
Return on Assets (Normalized)
 17.03%14.54%3.59%
Return on Equity (Normalized)
 53.42%150.11%9.12%
Return on Invested Capital (Normalized)
 26.30%28.30%5.88%
Return on Assets
RHHBY
ABBV
MRK
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Drug Manufacturers - General Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
LLY
Eli Lilly and CoVsghrmtxxVyb$709.2 Bil
JNJ
Johnson & JohnsonGjdkyxfHbq$351.2 Bil
MRK
Merck & Co IncPfxjksxTbyqb$317.2 Bil
ABBV
AbbVie IncKxfbgdzxZxdwr$291.6 Bil
AZN
AstraZeneca PLC ADRSvzfrbdtmnJhx$210.7 Bil
NVS
Novartis AG ADRTcpjpwwFmqs$189.7 Bil
PFE
Pfizer IncKqqbwqstPwtfn$143.8 Bil
AMGN
Amgen IncJgtvksrmrbSfr$140.9 Bil
SNY
Sanofi SA ADRDhsxwgtvRzk$113.5 Bil

Sponsor Center